Review of approved pioglitazone combinations for type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1571-1584

  Forst, Thomas ^a,b   Hanefeld, Markolf ^c   Pfützner, Andreas ^a,d  

^a IKFE Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c GWT   (Germany)

^d UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

combination therapy; diabetes mellitus type 2; insulin resistance; poglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ANTIINFLAMMATORY ACTIVITY; ANTITUMOR GENE; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EDEMA; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PANCREAS ISLET CELL FUNCTION; REVIEW; SIDE EFFECT; STROKE; VOMITING; WATER RETENTION; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PROGNOSIS; THIAZOLIDINEDIONES;

EID: 79958752323     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.567266     Document Type: Review

References (165)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7 (Pubitemid 34000780)
2. Pajunen P, Koukkunen H, Ketonen M, et al. Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study. Diabetologia 2005;48:2519-24 (Pubitemid 41738217)
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-6 (Pubitemid 46024990)
4. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000;101:1780-4 (Pubitemid 30213098)
5. Forst T, Pfutzner A, Lubben G, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism 2007;56:491-6 (Pubitemid 46437254)
6. Rewers M, Zaccaro D, Dagostino R, et al. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004;27:781-7 (Pubitemid 38280550)
7. Tenerz A, Norhammar A, Silveira A, et al. Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 2003;26:2770-6 (Pubitemid 37205545)
8. Forst T, Hohberg C, Pfutzner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009;41:123-31
9. Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulins vascular effects in humans. J Clin Invest 1994;94:2511-15 (Pubitemid 24379629)
10. Shankar RR, Wu Y, Shen HQ, et al. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 2000;49:684-7 (Pubitemid 30339980)
11. Forst T, Hohberg C, Pfutzner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009;41:123-31
12. Oh JY, Barrett-Connor E, Wedick NM. Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: the Rancho Bernardo Study. Circulation 2002;105:1311-16 (Pubitemid 34260421)
13. Roder ME, Porte D Jr, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:604-8 (Pubitemid 28496546)
14. Hostens K, Ling Z, Van Schravendijk C, Pipeleers D. Prolonged exposure of human beta-cells to high glucose increases their release of proinsulin during acute stimulation with glucose or arginine. J Clin Endocrinol Metab 1999;84:1386-90 (Pubitemid 30644404)
15. Seaquist ER, Kahn SE, Clark PM, et al. Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. J Clin Invest 1996;97:455-60 (Pubitemid 26039410)
16. Haffner SM, Mykkanen L, Stern MP, et al. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes 1993;42:1297-302 (Pubitemid 23259849)
17. Langenfeld MR, Forst T, Standl E, et al. IRIS II Study: sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther 2004;6:836-43 (Pubitemid 40129331)
18. Pfutzner A, Standl E, Hohberg C, et al. IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Diabetes Technol Ther 2005;7:478-86 (Pubitemid 40847810)
19. Kirchhoff K, Machicao F, Haupt A, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008;51:597-601
20. Yudkin JS, May M, Elwood P, et al. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 2002;45:327-36 (Pubitemid 34267354)
21. Wohlin M, Sundstrom J, Arnlov J, et al. Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men. Atherosclerosis 2003;170:181-5 (Pubitemid 37083578)
22. Lindahl B, Dinesen B, Eliasson M, et al. High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke 2000;31:2936-41
23. Alssema M, Dekker JM, Nijpels G, et al. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care 2005;28:860-5 (Pubitemid 40434486)
24. Galloway JA, Hooper SA, Spradlin CT, et al. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992;15:666-92
25. Lindahl B, Dinesen B, Eliasson M, et al. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism 1999;48:1197-202 (Pubitemid 29418294)
26. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-4 (Pubitemid 30367411)
27. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355:1008-10 (Pubitemid 30148273)
28. Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med 2001;79:30-47 (Pubitemid 32250021)
29. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000;60:333-43
30. Maeshiba Y, Kiyota Y, Yamashita K, et al. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997;47:29-35 (Pubitemid 27083325)
31. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168-78 (Pubitemid 38656403)
32. Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007;49:290-7 (Pubitemid 46110954)
33. Ghanim H, Dhindsa S, Aljada A, et al. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 2006;91:3553-8 (Pubitemid 44402137)
34. Esposito K, Ciotola M, Carleo D, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006;29:1071-6 (Pubitemid 44115246)
35. Horio T, Suzuki M, Takamisawa I, et al. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens 2005;18:1626-30 (Pubitemid 41814687)
36. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006;29:1039-45 (Pubitemid 44115241)
37. Pfutzner A, Schneider CA, Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther 2006;4:445-59 (Pubitemid 44304550)
38. Forst T, Hohberg C, Fuellert SD, et al. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 2005;37:521-7 (Pubitemid 41306404)
39. Forst T, Karagiannis E, Lubben G, et al. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2008;197:311-17 (Pubitemid 351273253)
40. Forst T, Weber MM, Lobig M, et al. Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus. Clin Sci (Lond) 2010;119:345-51
41. Winkler K, Konrad T, Fullert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003;26:2588-94 (Pubitemid 37052104)
42. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 study group. Diabetes Care 2000;23:1605-11
43. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-19 (Pubitemid 32888853)
44. Hanefeld M, Brunetti P, Schernthaner GH, et al.; QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7 (Pubitemid 38196723)
45. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
46. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104 (Pubitemid 39419498)
47. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone study group. Diabetes 1997;46:433-9 (Pubitemid 27090272)
48. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. N Engl J Med 1998;338:867-72 (Pubitemid 28135963)
49. Fullert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002;87:5503-6 (Pubitemid 36034352)
50. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004;27:484-90 (Pubitemid 38174076)
51. Vinik AI, Stansberry KB, Barlow PM. Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus. J Diabetes Complications 2003;17:279-85 (Pubitemid 37040775)
52. Forst T, Lubben G, Hohberg C, et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005;12:543-50 (Pubitemid 41632173)
53. Lloyd-Jones DM, Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med 1996;47:365-75 (Pubitemid 26138897)
54. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8
55. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6 (Pubitemid 28079219)
56. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-80 (Pubitemid 28475776)
57. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000;101:235-8 (Pubitemid 30054148)
58. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81 (Pubitemid 44903861)
59. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004;53:1382-6 (Pubitemid 39222104)
60. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-31 (Pubitemid 40696142)
61. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73 (Pubitemid 351482795)
62. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8 (Pubitemid 47403104)
63. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005;366:1279-89 (Pubitemid 41416583)
64. Macfarlane DP, Paterson KR, Fisher M. Oral antidiabetic agents as cardiovascular drugs. Diabetes Obes Metab 2007;9:23-30 (Pubitemid 44921038)
65. Donnelly R. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes. Int J Clin Pract 2007;61:1160-9 (Pubitemid 46934622)
66. Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009;50:1087-93
67. Gupta AK, Bray GA, Greenway FL, et al. Pioglitazone, but not metformin, reduces liver fat in type-2 diabetes mellitus independent of weight changes. J Diabetes Complications 2010;24:289-96
68. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104
69. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009;26:893-907
70. Magnusson I, Rothman DL, Katz LD, et al. Increased rate of gluconeogenesis in type 2 diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-7
71. Rossetti L, DeFronzo RA, Gherzi R, et al. Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations. Metabolism 1990;39:425-35 (Pubitemid 20146596)
72. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994;43:920-8 (Pubitemid 24196426)
73. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9 (Pubitemid 126537875)
74. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9
75. Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev 2008;4:340-56
76. Wulffele MG, Kooy A, de Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004;256:1-14 (Pubitemid 38813614)
77. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
78. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;259:1577-89
79. Kourelis T, Siegel R. Metformin and cancer: new applications for an old drug. 1-14, 2011 [Epub ahead of print]
80. Evans JM, Donnelly LA, Emslie-Smith AM. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5 (Pubitemid 40813563)
81. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care 2006;29:1990-1 (Pubitemid 44156679)
82. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33:322-6
83. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409 (Pubitemid 32056079)
84. Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-74 (Pubitemid 40467663)
85. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-104 (Pubitemid 40909644)
86. Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005;48:2477-81 (Pubitemid 41738210)
87. Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004;1:44-50
88. Pfutzner A, Efstrathios K, Lobig M, et al. Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays - an evaluation with samples from the PIOstat study. Clin Lab 2009;55:275-81
89. Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006;29:510-14 (Pubitemid 44115345)
90. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91 (Pubitemid 34655345)
91. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-9 (Pubitemid 35215326)
92. Feinglos MN, Bethel MA. Oral agent therapy in the treatment of type 2 diabetes. Diabetes Care 1999;22(Suppl 3):C61-4 (Pubitemid 29164919)
93. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003;26:1847-51 (Pubitemid 36929131)
94. Kabadi UM. Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents. Manag Care 2004;13:48-58
95. Ashcroft FM, Rorsman P, Trube G. Single calcium channel activity in mouse pancreatic beta-cells. Ann NY Acad Sci 1989;560:410-12 (Pubitemid 19226251)
96. Eliasson L, Renstrom E, Ammala C, et al. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells. Science 1996;271:813-15 (Pubitemid 26058934)
97. Lehtihet M, Welsh N, Berggren PO, et al. Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis. Am J Physiol Endocrinol Metab 2003;285:E438-46 (Pubitemid 36899720)
98. Draeger KE, Wernicke-Panten K, Lomp HJ, et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996;28:419-25 (Pubitemid 26343731)
99. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42 (Pubitemid 39120222)
100. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide research group. Horm Metab Res 1996;28:426-9 (Pubitemid 26343732)
101. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
102. Kahn SE, Haffner SM, Heise MA, et al.; United Kingdom Prospective Diabetes Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43 (Pubitemid 44903747)
103. Inoguchi T, Umeda F, Kakimoto M, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J 2000;47:763-70 (Pubitemid 32118490)
104. Zethelius B, Lithell H, Hales CN, Berne C. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Diabetologia 2005;48:862-7 (Pubitemid 40767978)
105. Zethelius B, Byberg L, Hales CN, et al. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation 2002;105:2153-8 (Pubitemid 34517158)
106. Pfutzner A, Kunt T, Hohberg C, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004;27:682-7 (Pubitemid 38280533)
107. Jia EZ, Yang ZJ, Zhu TB, et al. Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis. Cardiology 2007;110:106-11
108. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-6
109. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:169-74 (Pubitemid 43166269)
110. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
111. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008;17:753-9
112. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497
113. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8 (Pubitemid 41071035)
114. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008;31:1672-8
115. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
116. Danchin N, Charpentier G, Ledru F, et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005;21:143-9 (Pubitemid 40467660)
117. Tan A, Cao Y, Xia N, et al. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis. Eur J Intern Med 2010;21:398-403
118. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-7 (Pubitemid 32635256)
119. Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-7 (Pubitemid 34625022)
120. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004;116:230-5 (Pubitemid 38224230)
121. Tran MT, Navar MD, Davidson MB. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care 2006;29:1395-6 (Pubitemid 44125944)
122. Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2005;70:53-62 (Pubitemid 41207648)
123. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84 (Pubitemid 28162078)
124. Fukuen S, Iwaki M, Yasui A, et al. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 2005;280:23653-9 (Pubitemid 40884846)
125. Ueba H, Kuroki M, Hashimoto S, et al. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis 2005;183:35-9 (Pubitemid 41416819)
126. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492-8 (Pubitemid 16035703)
127. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705 (Pubitemid 46048557)
128. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20 (Pubitemid 28084232)
129. Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003;3:365-72 (Pubitemid 38906794)
130. Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84:3434-8 (Pubitemid 17085418)
131. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulindependent) diabetic patients. Diabetologia 1993;36:741-4 (Pubitemid 23218642)
132. Stumvoll M, Fritsche A, Stefan N, et al. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction. J Clin Endocrinol Metab 2001;86:1235-9 (Pubitemid 32323010)
133. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100 (Pubitemid 40616618)
134. Wang Y, Egan JM, Raygada M, et al. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 1995;136:4910-17
135. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992;130:159-66
136. Gromada J, Bokvist K, Ding WG, et al. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 1998;47:57-65 (Pubitemid 28030808)
137. MacDonald PE, Salapatek AM, Wheeler MB. Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 2002;51(Suppl 3):S443-7 (Pubitemid 35403428)
138. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50 (Pubitemid 351653542)
139. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment
140. Degn KB, Juhl CB, Sturis J, et al. One weeks treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94 (Pubitemid 38569002)
141. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
142. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:393-4
143. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85 (Pubitemid 351650556)
144. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475-80 (Pubitemid 46715627)
145. Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag 2008;4:1221-7
146. Kulasa K, Edelman S. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2010;5:23-37
147. Borja-Hart NL, Whalen, KL. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. Ann.Pharmacother 2010;44:1046-53
148. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442-51
149. Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med 2010;27:1409-19
150. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-17
151. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68 (Pubitemid 44841980)
152. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74 (Pubitemid 46206560)
153. Pratley RE, Reusch JE, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361-71
154. Triplitt C, Cersosimo E, DeFronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag 2010;6:671-90
155. Bailey CJ, Green BD, Flatt PR. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. Expert Opin Investig Drugs 2010;19:1017-25
156. Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010;42:663-9
157. Call R, Grimsley M, Cadwallader L, et al. Insulin - carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad Med 2010;122:158-65
158. Monami M, Lamanna C, Pala L, et al. Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. Exp Clin Endocrinol Diabetes 2008;116:184-9 (Pubitemid 351518539)
159. Yamanouchi T. Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Vasc Health Risk Manag 2010;6:189-97
160. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005;149:168-74 (Pubitemid 40126505)
161. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773-8 (Pubitemid 350083116)
162. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59 (Pubitemid 351831356)
163. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72 (Pubitemid 351831357)
164. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
165. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006;22:751-9